RU2008112676A - Противоопухолевое средство - Google Patents
Противоопухолевое средство Download PDFInfo
- Publication number
- RU2008112676A RU2008112676A RU2008112676/04A RU2008112676A RU2008112676A RU 2008112676 A RU2008112676 A RU 2008112676A RU 2008112676/04 A RU2008112676/04 A RU 2008112676/04A RU 2008112676 A RU2008112676 A RU 2008112676A RU 2008112676 A RU2008112676 A RU 2008112676A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- inclusion complex
- cyclodextrin
- cholestanol
- complex containing
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract 5
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract 10
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract 10
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 claims abstract 9
- -1 cholestanol compound Chemical class 0.000 claims abstract 9
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 201000011510 cancer Diseases 0.000 claims abstract 2
- 239000002502 liposome Substances 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims abstract 2
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical class C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
1. Противоопухолевое средство, включающее в качестве активного ингредиента холестанольное соединение, представленное следующей формулой (1): ! [Ф1] ! ! или циклодекстриновый комплекс включения, содержащий данное соединение. ! 2. Липосомная композиция, содержащая холестанольное соединение формулы (1), которое описано в п.1. ! 3. Циклодекстриновый комплекс включения, содержащий холестанольное соединение формулы (1), которое описано в п.1. ! 4. Комплекс включения по п.3, причем циклодекстрин является 2-гидроксипропил-β-циклодекстрином. ! 5. Применение холестанольного соединения, представленного следующей формулой (1): ! [Ф2] ! ! или циклодекстринового комплекса включения, содержащего соединение для получения противоопухолевого средства. ! 6. Способ профилактики или лечения рака, отличающийся тем, что включает введение холестанольного соединения, представленного следующей формулой (1): ! [Ф3] ! ! или циклодекстринового комплекса включения, содержащего данное соединение.
Claims (6)
1. Противоопухолевое средство, включающее в качестве активного ингредиента холестанольное соединение, представленное следующей формулой (1):
[Ф1]
или циклодекстриновый комплекс включения, содержащий данное соединение.
2. Липосомная композиция, содержащая холестанольное соединение формулы (1), которое описано в п.1.
3. Циклодекстриновый комплекс включения, содержащий холестанольное соединение формулы (1), которое описано в п.1.
4. Комплекс включения по п.3, причем циклодекстрин является 2-гидроксипропил-β-циклодекстрином.
5. Применение холестанольного соединения, представленного следующей формулой (1):
[Ф2]
или циклодекстринового комплекса включения, содержащего соединение для получения противоопухолевого средства.
6. Способ профилактики или лечения рака, отличающийся тем, что включает введение холестанольного соединения, представленного следующей формулой (1):
[Ф3]
или циклодекстринового комплекса включения, содержащего данное соединение.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005255517 | 2005-09-02 | ||
| JP2005-255517 | 2005-09-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008112676A true RU2008112676A (ru) | 2009-10-10 |
| RU2410389C2 RU2410389C2 (ru) | 2011-01-27 |
Family
ID=37808952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008112676/04A RU2410389C2 (ru) | 2005-09-02 | 2006-09-01 | Противоопухолевое средство |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7968116B2 (ru) |
| EP (1) | EP1921086B1 (ru) |
| JP (1) | JP5011113B2 (ru) |
| KR (1) | KR101292539B1 (ru) |
| CN (1) | CN101253192B (ru) |
| AR (1) | AR057793A1 (ru) |
| AU (1) | AU2006285678B2 (ru) |
| BR (1) | BRPI0615196A2 (ru) |
| CA (1) | CA2621377C (ru) |
| CY (1) | CY1115196T1 (ru) |
| DK (1) | DK1921086T3 (ru) |
| ES (1) | ES2459767T3 (ru) |
| HR (1) | HRP20140439T1 (ru) |
| IL (1) | IL189752A (ru) |
| MY (1) | MY155903A (ru) |
| NO (1) | NO20081125L (ru) |
| PL (1) | PL1921086T3 (ru) |
| PT (1) | PT1921086E (ru) |
| RU (1) | RU2410389C2 (ru) |
| SI (1) | SI1921086T1 (ru) |
| TW (1) | TWI373473B (ru) |
| WO (1) | WO2007026869A1 (ru) |
| ZA (1) | ZA200802813B (ru) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ300722B6 (cs) * | 2006-09-27 | 2009-07-22 | Univerzita Karlova v Praze, Prírodovedecká fakulta | Zpusob prípravy inkluzního komplexu pentacyklických a tetracyklických terpenoidu a farmaceutického prostredku obsahujícího tento inkluzní komplex, inkluzní komplex pentacyklického nebo tetracyklického terpenoidu a farmaceutický prostredek obsahující |
| TWI492759B (zh) | 2008-03-05 | 2015-07-21 | Otsuka Pharma Co Ltd | 膽甾烷醇衍生物之併用用途 |
| SI2404608T1 (sl) * | 2009-03-04 | 2015-06-30 | Otsuka Pharmaceutical Co., Ltd. | Holestanolni derivat za kombinirano uporabo |
| EP2415464B1 (en) * | 2009-03-30 | 2017-05-10 | Eisai R&D Management Co., Ltd. | Method for producing liposome composition |
| KR101495951B1 (ko) | 2009-03-30 | 2015-02-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 리포솜 조성물 |
| CN104487059B (zh) | 2012-03-02 | 2017-06-23 | 伊利诺伊大学评议会 | 由双重化合物激活的强有效的抗癌活性 |
| US9421202B2 (en) | 2012-03-06 | 2016-08-23 | The Board Of Trustees Of The University Of Illinois | Procaspase combination therapy for glioblastoma |
| KR102074530B1 (ko) | 2012-03-06 | 2020-02-06 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | 조합 요법에 의한 프로카스파제 ３ 활성화 |
| CN103349948B (zh) * | 2013-06-21 | 2015-05-27 | 江南大学 | 一种植物甾烷醇微胶囊化方法 |
| CN105753923B (zh) * | 2014-12-17 | 2017-09-29 | 富力 | 20(R)‑人参皂苷Rg3多酰基化衍生物、制备及其应用 |
| EP3449921B1 (en) | 2016-04-28 | 2023-05-31 | Eisai R&D Management Co., Ltd. | Eribulin for inhibiting tumor growth |
| CA3082575A1 (en) | 2017-11-17 | 2019-05-23 | The Board Of Trustees Of The University Of Illinois | Cancer therapy by degrading dual mek signaling |
| US12090153B2 (en) | 2018-10-05 | 2024-09-17 | The Board Of Trustees Of The University Of Illinois | Combination therapy for the treatment of uveal melanoma |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS572300A (en) | 1980-06-09 | 1982-01-07 | Tetsuo Suami | Novel nitrosourea derivative |
| SE8902235D0 (sv) * | 1989-06-20 | 1989-06-20 | Haessle Ab | Novel cyclodextrin inclusion complexes |
| JP4105258B2 (ja) * | 1997-08-19 | 2008-06-25 | 大塚製薬株式会社 | コレスタノール化合物及びこれを含有する医薬 |
| JPH11160592A (ja) | 1997-11-28 | 1999-06-18 | Hitachi Cable Ltd | 光ファイバケーブル用スペーサ |
| JP4351314B2 (ja) * | 1998-12-24 | 2009-10-28 | 大塚製薬株式会社 | コレスタノール化合物及びこれを含有する医薬 |
| CA2529992C (en) * | 2003-07-17 | 2011-11-22 | Otsuka Pharmaceutical Co., Ltd. | Glycoside-containing liposome |
| DK1709063T3 (da) * | 2003-12-18 | 2008-06-02 | Unibioscreen Sa | Glycosyleret steroidderivat med anti-migratorisk aktivitet |
| JP2005225822A (ja) * | 2004-02-13 | 2005-08-25 | Konica Minolta Medical & Graphic Inc | リポソーム含有ｘ線造影剤 |
| KR100603814B1 (ko) * | 2004-03-11 | 2006-07-25 | 바이오스펙트럼 주식회사 | 나노리포좀 조성물 |
-
2006
- 2006-08-23 TW TW095131026A patent/TWI373473B/zh not_active IP Right Cessation
- 2006-09-01 PL PL06797258T patent/PL1921086T3/pl unknown
- 2006-09-01 MY MYPI20080147A patent/MY155903A/en unknown
- 2006-09-01 JP JP2007533352A patent/JP5011113B2/ja not_active Expired - Fee Related
- 2006-09-01 SI SI200631773T patent/SI1921086T1/sl unknown
- 2006-09-01 AU AU2006285678A patent/AU2006285678B2/en not_active Ceased
- 2006-09-01 BR BRPI0615196-5A patent/BRPI0615196A2/pt not_active IP Right Cessation
- 2006-09-01 CA CA2621377A patent/CA2621377C/en not_active Expired - Fee Related
- 2006-09-01 PT PT67972588T patent/PT1921086E/pt unknown
- 2006-09-01 EP EP06797258.8A patent/EP1921086B1/en active Active
- 2006-09-01 ZA ZA200802813A patent/ZA200802813B/xx unknown
- 2006-09-01 HR HRP20140439TT patent/HRP20140439T1/hr unknown
- 2006-09-01 RU RU2008112676/04A patent/RU2410389C2/ru not_active IP Right Cessation
- 2006-09-01 WO PCT/JP2006/317316 patent/WO2007026869A1/ja not_active Ceased
- 2006-09-01 ES ES06797258.8T patent/ES2459767T3/es active Active
- 2006-09-01 DK DK06797258.8T patent/DK1921086T3/da active
- 2006-09-01 CN CN2006800314977A patent/CN101253192B/zh not_active Expired - Fee Related
- 2006-09-01 KR KR1020087006194A patent/KR101292539B1/ko not_active Expired - Fee Related
- 2006-09-01 US US11/997,579 patent/US7968116B2/en not_active Expired - Fee Related
- 2006-09-01 AR ARP060103846A patent/AR057793A1/es unknown
-
2008
- 2008-02-25 IL IL189752A patent/IL189752A/en not_active IP Right Cessation
- 2008-03-04 NO NO20081125A patent/NO20081125L/no not_active Application Discontinuation
-
2014
- 2014-06-20 CY CY20141100450T patent/CY1115196T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200802813B (en) | 2009-10-28 |
| CA2621377A1 (en) | 2007-03-08 |
| MY155903A (en) | 2015-12-15 |
| AR057793A1 (es) | 2007-12-19 |
| PT1921086E (pt) | 2014-04-29 |
| KR20080043838A (ko) | 2008-05-19 |
| DK1921086T3 (da) | 2014-05-05 |
| CY1115196T1 (el) | 2017-01-04 |
| AU2006285678B2 (en) | 2012-01-19 |
| NO20081125L (no) | 2008-05-16 |
| RU2410389C2 (ru) | 2011-01-27 |
| PL1921086T3 (pl) | 2014-09-30 |
| HRP20140439T1 (hr) | 2014-06-20 |
| ES2459767T3 (es) | 2014-05-12 |
| JP5011113B2 (ja) | 2012-08-29 |
| US7968116B2 (en) | 2011-06-28 |
| EP1921086B1 (en) | 2014-04-16 |
| IL189752A (en) | 2013-07-31 |
| US20100292176A1 (en) | 2010-11-18 |
| TWI373473B (en) | 2012-10-01 |
| SI1921086T1 (sl) | 2014-05-30 |
| WO2007026869A1 (ja) | 2007-03-08 |
| AU2006285678A1 (en) | 2007-03-08 |
| JPWO2007026869A1 (ja) | 2009-03-12 |
| KR101292539B1 (ko) | 2013-08-20 |
| CN101253192B (zh) | 2011-05-04 |
| BRPI0615196A2 (pt) | 2011-05-10 |
| CA2621377C (en) | 2013-10-22 |
| EP1921086A1 (en) | 2008-05-14 |
| CN101253192A (zh) | 2008-08-27 |
| EP1921086A4 (en) | 2012-07-25 |
| TW200738744A (en) | 2007-10-16 |
| HK1115140A1 (en) | 2008-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008112676A (ru) | Противоопухолевое средство | |
| BRPI0607455A2 (pt) | composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica | |
| TW200716606A (en) | Chemical compounds | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| CY1113011T1 (el) | Νεα κρυσταλλικη μορφη v της αγομελατινης, μεθοδος παρασκευης αυτης και φαρμακευτικες συνθεσεις που περιεχουν αυτην | |
| CY1110900T1 (el) | Χημικες ενωσεις | |
| BRPI0510177B8 (pt) | composto, composição farmacêutica e uso do mesmo | |
| UA103319C2 (en) | Thiazole- and oxazole-benzene sulfonamide compounds | |
| CY1109369T1 (el) | Υποκατεστημενες πυρρολοπυριδινες, οι ενωσεις που τις περιεχουν, η διαδικασια παρασκευης τους και η χρηση τους | |
| WO2008009831A3 (fr) | Derives de cyclodextrines amphiphiles | |
| PH12012501199A1 (en) | Chalcones as enhancer of antimicrobial agents | |
| PT2049480E (pt) | Derivados de 2-arilindole como inibidores da mpges-i | |
| AU2003300385A8 (en) | Anticancer compounds | |
| TW200504042A (en) | Combretastatin derivatives with cytotoxic action | |
| MY144782A (en) | Glucuronate salt of a piperazine compound | |
| WO2004087673A3 (en) | Migrastatin analogs and uses thereof | |
| WO2006133397A3 (en) | Process for the synthesis of triazoles | |
| RU2009138470A (ru) | Композиция для наружного применения на коже | |
| JP2006124384A5 (ru) | ||
| RU2012137206A (ru) | Лигнангидроксилаза | |
| TW200613317A (en) | Steroid prodrugs with androgenic action | |
| TW200613315A (en) | Estradiol prodrugs | |
| TW200612962A (en) | Estriol and estetrol prodrugs | |
| WO2006023586A3 (en) | Guanylhydrazone compounds, compositions, methods of making and using | |
| TW200600013A (en) | 5,6-Dialkyl-7-aminotriazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160902 |